BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 37455550)

  • 1. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
    Zhang J; Zhang Y; Khanal S; Cao D; Zhao J; Dang X; Nguyen LNT; Schank M; Wu XY; Jiang Y; Ning S; Wang L; El Gazzar M; Moorman JP; Guo H; Yao ZQ
    J Med Virol; 2023 Jul; 95(7):e28952. PubMed ID: 37455550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.
    Martinez MG; Combe E; Inchauspe A; Mangeot PE; Delberghe E; Chapus F; Neveu G; Alam A; Carter K; Testoni B; Zoulim F
    mBio; 2022 Apr; 13(2):e0288821. PubMed ID: 35389262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.
    Yang HC; Chen PJ
    Virus Res; 2018 Jan; 244():304-310. PubMed ID: 28627393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication.
    Wang J; Xu ZW; Liu S; Zhang RY; Ding SL; Xie XM; Long L; Chen XM; Zhuang H; Lu FM
    World J Gastroenterol; 2015 Aug; 21(32):9554-65. PubMed ID: 26327763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
    Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
    Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus.
    Kostyushev D; Brezgin S; Kostyusheva A; Zarifyan D; Goptar I; Chulanov V
    Cell Mol Life Sci; 2019 May; 76(9):1779-1794. PubMed ID: 30673820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA.
    Kayesh MEH; Amako Y; Hashem MA; Murakami S; Ogawa S; Yamamoto N; Hifumi T; Miyoshi N; Sugiyama M; Tanaka Y; Mizokami M; Kohara M; Tsukiyama-Kohara K
    Virus Res; 2020 Dec; 290():198191. PubMed ID: 33049308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
    Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K
    World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered extracellular vesicles for delivering functional Cas9/gRNA to eliminate hepatitis B virus cccDNA and integration.
    Zeng W; Zheng L; Li Y; Yang J; Mao T; Zhang J; Liu Y; Ning J; Zhang T; Huang H; Chen X; Lu F
    Emerg Microbes Infect; 2024 Dec; 13(1):2284286. PubMed ID: 37982370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic gRNA/Cas9 Ribonucleoprotein Inhibits HIV Reactivation and Replication.
    Khanal S; Cao D; Zhang J; Zhang Y; Schank M; Dang X; Nguyen LNT; Wu XY; Jiang Y; Ning S; Zhao J; Wang L; Gazzar ME; Moorman JP; Yao ZQ
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models.
    Yi J; Lei X; Guo F; Chen Q; Chen X; Zhao K; Zhu C; Cheng X; Lin J; Yin H; Xia Y
    Antiviral Res; 2023 Jul; 215():105618. PubMed ID: 37142191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.
    Moyo B; Bloom K; Scott T; Ely A; Arbuthnot P
    Virus Res; 2018 Jan; 244():311-320. PubMed ID: 28087399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The gRNA-miRNA-gRNA Ternary Cassette Combining CRISPR/Cas9 with RNAi Approach Strongly Inhibits Hepatitis B Virus Replication.
    Wang J; Chen R; Zhang R; Ding S; Zhang T; Yuan Q; Guan G; Chen X; Zhang T; Zhuang H; Nunes F; Block T; Liu S; Duan Z; Xia N; Xu Z; Lu F
    Theranostics; 2017; 7(12):3090-3105. PubMed ID: 28839466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus.
    Liu Y; Zhao M; Gong M; Xu Y; Xie C; Deng H; Li X; Wu H; Wang Z
    Antiviral Res; 2018 Apr; 152():58-67. PubMed ID: 29458131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of CRISPR/Cas9 Technology to HBV.
    Lin G; Zhang K; Li J
    Int J Mol Sci; 2015 Nov; 16(11):26077-86. PubMed ID: 26540039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9.
    Li H; Sheng C; Wang S; Yang L; Liang Y; Huang Y; Liu H; Li P; Yang C; Yang X; Jia L; Xie J; Wang L; Hao R; Du X; Xu D; Zhou J; Li M; Sun Y; Tong Y; Li Q; Qiu S; Song H
    Front Cell Infect Microbiol; 2017; 7():91. PubMed ID: 28382278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pregenomic RNA Launch Hepatitis B Virus Replication System Facilitates the Mechanistic Study of Antiviral Agents and Drug-Resistant Variants on Covalently Closed Circular DNA Synthesis.
    Zhao Q; Chang J; Rijnbrand R; Lam AM; Sofia MJ; Cuconati A; Guo JT
    J Virol; 2022 Dec; 96(24):e0115022. PubMed ID: 36448800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.
    Peng C; Lu M; Yang D
    Virol Sin; 2015 Oct; 30(5):317-25. PubMed ID: 26511989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas.
    Yang YC; Yang HC
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy.
    Murai K; Kodama T; Hikita H; Shimoda A; Fukuoka M; Fukutomi K; Shigeno S; Shiode Y; Motooka D; Higuchi Y; Miyakawa K; Suemizu H; Ryo A; Tahata Y; Makino Y; Yamada R; Sakamori R; Tatsumi T; Takehara T
    Hepatol Commun; 2022 Sep; 6(9):2474-2487. PubMed ID: 35608131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.